About Parkinson's Disease (PD) Drugs
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80%. This decrease in dopamine levels leads to symptoms associated with PD such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed after the age of 50 years; however, cases of earlier incidence have also been reported.
Technavio’s analysts forecast the global parkinson's disease (PD) drugs market to grow at a CAGR of 3.81% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global parkinson's disease (PD) drugs market for 2017-2021. To calculate the market size, the report considers sales/revenues and market share of the PD drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Parkinson's Disease (PD) Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global parkinson's disease (PD) drugs market: Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharmaceutical Industries.
Other Prominent Vendors in the market are: AbbVie, Abital Pharma, Addex Therapeutics, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, H. Lundbeck, Impax Laboratories, Kyowa Hakko Kirin, Otsuka Pharmaceutical, Pfizer, Prana Biotechnology, Reviva Pharmaceuticals, SK Biopharmaceuticals, Takeda Pharmaceutical, and UCB.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of biomarkers. The global PD drugs market is primarily dominated by dopamine agonist, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others. Use of these drugs for the treatment of different types of neurodegenerative disorders such as Lewy bodies dementia, movement disorder, and PD indicates that these disorders have common pathological conditions.”
According to the report, one driver in the market is rise in geriatric population. PD is a neurological disorder, often characterized by a decline in motor functions, cognitive, and memory impairments. The cognitive impairment associated with PD may include symptoms such as memory loss, difficulty in understanding words, inability to carry out voluntary activities, failure to identify objects, and others. The risk of developing PD increases with age and is more common among older people. As per the CDC, the projected demographic changes in the US and increasing geriatric population demand better understanding of the pathogenesis of various neurological diseases, including dementia, among older population and is a growing public health concern.
Further, the report states that one challenge in the market is entry of generics. Generic drugs are often introduced once the patent on the branded drugs expires. Patent expiries led to the introduction of less expensive generic drugs in the market. The global PD drugs market has also witnessed the loss of patent exclusivity period of various blockbuster drugs, which has led to the entry of generics during the forecast period. Many generic products currently serve the market. For instance, the patent expiry of top-selling drugs such as Aricept from Eisai has led to decrease in the revenue potential of the market in the recent years, and entry of generic donepezil are hampering the market growth.
Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical Industries, AbbVie, Abital Pharma, Addex Therapeutics, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, H. Lundbeck, Impax Laboratories, Kyowa Hakko Kirin, Otsuka Pharmaceutical, Pfizer, Prana Biotechnology, Reviva Pharmaceuticals, SK Biopharmaceuticals, Takeda Pharmaceutical, and UCB.